UK molecular diagnostics firm Lab21 has agreed to merge with French firm Novacyt, gaining a listing on the Alternext exchange in Paris and a presence in the cervical cancer screening market in the process.
The stock-based reverse takeover will see Lab21’s shareholders receiving around 2.5 million Novacyt shares at an exchange ratio of 0.925...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?